Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V114 in Healthy Adults and Infants
NCT02037984Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2014
- Primary completion
- Jul 2016
- Modality
- Split/Subunit Vaccines
01
Overview
A Phase 2 trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Jan 2014; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02037984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02037984.